Skip to main content

Illumina, Inc. (ILMN)

NASDAQ: ILMN · Delayed Price · USD
438.00 -9.01 (-2.02%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap69.36B
Revenue (ttm)3.97B
Net Income (ttm)768.00M
Shares Out146.00M
EPS (ttm)5.22
PE Ratio83.88
Forward PE64.94
Dividendn/a
Ex-Dividend Daten/a
Volume920,361
Open440.67
Previous Close447.01
Day's Range433.00 - 449.99
52-Week Range260.42 - 555.77
Beta0.90
AnalystsHold
Price Target459.00 (+4.8%)
Est. Earnings DateOct 28, 2021

About ILMN

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers i...

IndustryLife Sciences Tools & Services
IPO DateJul 28, 2000
CEOFrancis deSouza
Employees7,800
Stock ExchangeNASDAQ
Ticker SymbolILMN
Full Company Profile

Financial Performance

In 2020, Illumina's revenue was $3.24 billion, a decrease of -8.58% compared to the previous year's $3.54 billion. Earnings were $656.00 million, a decrease of -34.53%.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for Illumina stock is "Hold." The 12-month stock price forecast is 459.00, which is an increase of 4.79% from the latest price.

Price Target
$459.00
(4.79% upside)
Analyst Consensus: Hold

News

Illumina says it had expected EU hold order on Grail

U.S. life sciences company Illumina said on Monday that it had anticipated an order from EU antitrust enforcers to keep recently acquired Grail as a separate company while waiting for regulatory clearan...

13 hours ago - Reuters

EU regulators impose interim measures against Illumina in Grail deal

EU antitrust regulators on Monday announced interim measures against U.S. life sciences company Illumina for for closing its $8 billion cash-and-stock takeover of cancer detection test maker Grail deal ...

17 hours ago - Reuters

Illumina Ventures Closes $325 Million Fund

SAN FRANCISCO--(BUSINESS WIRE)--Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 mil...

20 hours ago - Business Wire

The 1 Stock I'd Buy Right Now

The pandemic isn't over yet.

Other symbols:EXASFLGTGH
2 days ago - The Motley Fool

5 Medtech Stocks to Seize Major Growth

The merging of healthcare and technology is changing how we care for our bodies. It's also creating investment opportunities, such as these five medical technology stocks.

Other symbols:DXCMTDOCVEEV
5 days ago - Kiplinger

Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle

SAN DIEGO, Sept. 15, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator.

5 days ago - PRNewsWire

Illumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050

SAN DIEGO, Sept. 9, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) elevates climate action goals with commitments for net zero greenhouse gas emissions aligned with the Paris Agreement, commits to v...

1 week ago - PRNewsWire

Illumina (ILMN), Merck Ink Cancer Companion Diagnostics Deal

Illumina (ILMN) collaborated with Merck to develop and commercialize companion diagnostics to identify ovarian cancer patients with positive HRD status for treatment with LYNPARZA.

Other symbols:MRK
1 week ago - Zacks Investment Research

Illumina, Merck Join Hands For Homologous Recombination Deficiency CDx, Research Assay

Illumina Inc (NASDAQ: ILMN) and Merck & Co Inc (NYSE: MRK) provided more details on their partnership to develop and commercialize tests that gauge genetic mutations involved in homologous recombination...

Other symbols:MRK
1 week ago - Benzinga

Why Illumina Wants Grail Back So Badly

The gene-sequencing giant sees a huge opportunity in diagnostics.

2 weeks ago - The Motley Fool

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic Rev...

Other symbols:BEAMEDITNTLA
2 weeks ago - InvestorPlace

U.S. lawmakers question FTC's efforts to stop Illumina's deal for Grail

Two Republican lawmakers on Thursday questioned the Federal Trade Commission's efforts to unwind life science company Illumina Inc's $7.1 billion acquisition of Grail Inc, alleging the regulator was not...

2 weeks ago - Reuters

3 Stocks These ESG Gurus Agree On

Former Vice President Al Gore (Trades, Portfolio), leader of Generation Investment Management, and Jerome Dodson (Trades, Portfolio)'s Parnassus Investments may take slightly different approaches to ide...

Other symbols:GWRESNPS
2 weeks ago - GuruFocus

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO, Aug. 30, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Morgan Stanley 19th Annual Global Health...

3 weeks ago - PRNewsWire

Illumina (ILMN), Grail Merger Sees Futher Regulatory Challenges

According to Illumina (ILMN), GRAIL will continue to operate as a separate company until the ongoing regulatory review by the EC is completed.

3 weeks ago - Zacks Investment Research

FTC urges judge to unwind $7.1 billion Illumina-Grail merger

The U.S. Federal Trade Commission on Tuesday said it seeks to unwind life science company Illumina Inc's $7.1 billion acquisition of Grail Inc, alleging it would harm innovation and boost prices.

3 weeks ago - Reuters

7 Great Growth Stocks to Buy Now to Build Your Portfolio

These growth stocks could boost growth portfolios in the coming quarters The post 7 Great Growth Stocks to Buy Now to Build Your Portfolio appeared first on InvestorPlace. More From InvestorPlace Stock ...

3 weeks ago - InvestorPlace

Will Illumina Stock Rebound After A 6% Fall Last Week?

The stock price of Illumina, a gene sequencing company, reached an all-time high of $524 earlier this month before a recent sell-off drove the stock price down 6% to its current level of around $487. IL...

3 weeks ago - Forbes

Illumina (ILMN) Shares Slip on GRAIL Buyout Deal Completion

Illumina (ILMN) acquisition of GRAIL will expand patient access to life-saving multi-cancer early-detection test.

4 weeks ago - Zacks Investment Research

Illumina CEO on why the company moved forward with Grail deal, in spite of FTC challenge

Frances deSouza, Illumina CEO, joins Power Lunch to discuss his company's deal to buy cancer diagnostics company Grail, in spite of a challenge from the FTC. For access to live and exclusive video from ...

1 month ago - CNBC Television

Illumina in EU antitrust sights over premature $8 billion Grail deal

U.S. life sciences company Illumina could face a hefty fine for jumping the gun by completing its $8 billion cash-and-stock takeover of cancer detection test maker Grail without first securing EU antitr...

1 month ago - Reuters

Why Illumina Stock Just Dropped 10%

The genetic-testing company just blatantly defied its regulators.

1 month ago - The Motley Fool

Illumina Completes Grail Buyout Despite Uncertainty In Regulatory Process

In defiance of FTC and EU scrutiny, Illumina Inc (NASDAQ: ILMN) went ahead to complete its $8 billion acquisition of Grail. The finalization of the buyout comes as the FTC sued to block the move in Marc...

1 month ago - Benzinga

Illumina closes $7.1 billion deal for cancer test maker Grail amid regulatory hurdles

Illumina Inc has completed its $7.1 billion acquisition of cancer detection test maker Grail Inc, it said on Wednesday amid challenges posed by the U.S. Federal Trade Commission and the European Union a...

1 month ago - Reuters

Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test

SAN DIEGO, Aug. 18, 2021 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but wi...

1 month ago - PRNewsWire